by Admin | Mar 3, 2026
Stability, Durability, and the “Scar-Free” Manufacturing Frontier The clinical triumph of linear mRNA during the pandemic proved that RNA could be a “sprinter”—rapidly deployed and highly effective for transient immune activation. However, as...
by Admin | Feb 11, 2026
In February 2026, the mRNA and cell therapy sectors witnessed a strategic shift toward in vivo applications and more durable RNA constructs. As multinational pharmaceutical companies (MNCs) seek to overcome the logistical hurdles of traditional CAR-T, the spotlight...
by Admin | Jan 27, 2026
In January 2026, a cluster of Nipah virus (NiV) cases emerged in West Bengal, India, resulting in five confirmed infections and nearly a hundred individuals under observation. Neighboring countries have already initiated border screenings, as this “Priority...
by Admin | Oct 30, 2025
Chimeric Antigen Receptor (CAR) T-cell therapy has already revolutionized the fight against blood cancers, but its current form—a complex, expensive, and time-intensive process that involves extracting a patient’s T cells, shipping them to a lab for engineering...
by Admin | Aug 15, 2025
As the field of mRNA therapeutics continues to expand—spanning vaccines, oncology, protein replacement, and gene editing—scientists are constantly optimizing their tools to improve safety, efficacy, and durability. One of the most impactful innovations in this space...
by Admin | Jul 30, 2025
Self-amplifying RNA (saRNA) is gaining momentum as the next frontier in RNA therapeutics and vaccine development. By integrating an RNA replicon system derived from alphaviruses, saRNA enables amplification of the target antigen in vivo, potentially reducing the...
